--- title: "Syndax Pharmaceuticals (SNDX) news: offering" url: "https://aibio.space/companies/syndax-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SNDX offering and convertible notes news: Syndax agrees to $250.0 million private placement of 2.25% convertible notes. Syndax Pharmaceuticals, Inc." --- SNDX Syndax Pharmaceuticals, Inc. NASDAQ · United States # Syndax Pharmaceuticals (SNDX) news SNDX offering and convertible notes news Debt Financing · 2026-06-04 ## [Syndax agrees to $250.0 million private placement of 2.25% convertible notes](https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/) Syndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million. ## Latest Syndax Pharmaceuticals news 1. 2026-06-04 Debt Financing [Syndax agrees to sell $250.0 million of 2.25% convertible notes due 2031](https://aibio.space/news/syndax-agrees-sell-250-0-million-2-25-percent-convertible-notes-due/) Syndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share. ## Syndax Pharmaceuticals at a glance - **Ticker**: SNDX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $547.9 million ### Related companies - [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG - [MeiraGTx Holdings](https://aibio.space/companies/meiragtx/) NASDAQ: MGTX - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Spero Therapeutics](https://aibio.space/companies/spero-therapeutics/) NASDAQ: SPRO - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM ### Also on NASDAQ - [Nyxoah SA](https://aibio.space/companies/nyxoah/) NYXH - [CAMP4 Therapeutics](https://aibio.space/companies/camp4-therapeutics/) CAMP - [Cytokinetics](https://aibio.space/companies/cytokinetics/) CYTK - [SERA PROGNOSTICS, INC.](https://aibio.space/companies/sera-prognostics/) SERA - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) TKNO - [ProQR Therapeutics](https://aibio.space/companies/proqr-therapeutics-n-v/) PRQR ## Syndax Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$172.4 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | [$23.7 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | | Research and development | [$258.8 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | [$241.6 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | | Net income (loss) | [-$285.4 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | [-$318.8 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | | Cash from operations | [-$323.0 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | [-$274.9 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | | Cash and equivalents | [$134.9 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/) | [$154.1 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | | Short-term investments | [$259.1 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/) | [$418.8 million](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $336.5 million, plus short-term investments of $211.4 million, $547.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Syndax Pharmaceuticals Has Syndax Pharmaceuticals raised money recently? Our latest story on this, dated Jun 4, 2026: "Syndax agrees to $250.0 million private placement of 2.25% convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/). Has Syndax Pharmaceuticals sold convertible notes? Our latest story on this, dated Jun 4, 2026: "Syndax agrees to $250.0 million private placement of 2.25% convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/). What is the ticker symbol of Syndax Pharmaceuticals? Syndax Pharmaceuticals, Inc. trades under the ticker SNDX on NASDAQ. Where is Syndax Pharmaceuticals listed? Syndax Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1T3; LS:A2AFL6; LSX:A2AFL6. What is the SEC CIK of Syndax Pharmaceuticals? The SEC Central Index Key (CIK) for Syndax Pharmaceuticals, Inc. is 1395937. Its filings are on SEC EDGAR. How many shares does Syndax Pharmaceuticals have outstanding? 89,297,086 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Syndax Pharmaceuticals listed under? Our directory records Syndax Pharmaceuticals, Inc. under United States. What does Syndax Pharmaceuticals do? Our directory classifies Syndax Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Syndax Pharmaceuticals? The ISIN recorded for Syndax Pharmaceuticals, Inc. is US87164F1057. Does aibio.space cover Syndax Pharmaceuticals? aibio.space lists Syndax Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Syndax Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was Syndax Pharmaceuticals's revenue last year? $172.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Syndax Pharmaceuticals profitable? Syndax Pharmaceuticals, Inc. reported a net loss of $285.4 million for the fiscal year ended Dec 31, 2025, and used $323.0 million of cash in operations, per its annual report to the SEC. How much does Syndax Pharmaceuticals spend on research and development? $258.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Syndax Pharmaceuticals have? $547.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Syndax Pharmaceuticals Members talk about Syndax Pharmaceuticals (SNDX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Syndax Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-06-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SNDX on TradingView](https://www.tradingview.com/symbols/NASDAQ-SNDX/). ## SEC filings and registration - **SEC name**: Syndax Pharmaceuticals Inc - **CIK**: 1395937 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SNDX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 730 THIRD AVENUE, NEW YORK, NY, 10017 - **Phone**: 781-419-1400 - **Shares outstanding**: 89,297,086 as of 2026-07-31 (10-Q filed 2026-08-04) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/sndx-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/sndx-20260714.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/d105044d8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/sndx-20260610.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010d8k.htm) filed 2026-06-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1395937/000119312526197859/sndx-20260430.htm) filed 2026-04-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000119312526197154/sndx-20260331.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001395937), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Syndax Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SNDX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Syndax Pharmaceuticals, Inc. - **Ticker**: SNDX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US87164F1057 - **Other listed symbols**: GETTEX:1T3; LS:A2AFL6; LSX:A2AFL6 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SNDX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/syndax-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Syndax Pharmaceuticals (SNDX) news: offering", 2026-10-31, https://aibio.space/companies/syndax-pharmaceuticals/